<DOC>
	<DOCNO>NCT00191477</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled Phase 3 multicenter study assess efficacy safety intravesical instillation gemcitabine versus placebo immediately transurethral resection bladder tumor .</brief_summary>
	<brief_title>Instillation Gemcitabine Patients With Superficial Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Clinical evidence superficial transitional cell carcinoma bladder Males females least 18 year age Karnofsky Performance Status great equal 70 % Patient compliance geographic proximity allow adequate followup Female patient reproductive potential must use reliable contraceptive method appropriate ( example , intrauterine device [ IUD ] , birth control pill , barrier device ) study . Female patient reproductive potential must negative serum pregnancy test within 7 day study enrollment . Signed informed consent . Clinical evidence muscleinvasive locally advanced bladder cancer Clinical evidence upper urinary tract tumor Distant metastases Other malignancy within last 2 year , except nonmelanotic skin tumor , carcinoma situ cervix organconfined prostate cancer curative therapy Severe concomitant psychiatric disease Febrile , active infection Other serious concomitant disorder would compromise safety patient his/her ability complete study accord protocol , discretion investigator ( example , unstable angina pectoris , uncontrolled diabetes mellitus )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>